Clinuvel Pharmaceuticals Limited (AU:CUV) has released an update.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Clinuvel Pharmaceuticals is in advanced discussions with the European Medicines Agency to potentially expand the dosage of its SCENESSE® drug for patients with erythropoietic protoporphyria (EPP) from the current recommendation of four doses to up to six annually. This move aims to harmonize the European usage with other regions like the US, ensuring patients receive consistent year-round treatment. An EMA decision is anticipated in the first quarter of 2025, which could significantly impact the drug’s market and patient care strategy.
For further insights into AU:CUV stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Another Paramount+ (NASDAQ:PARA) Price Hike Hits Europe
- Ford (NYSE:F) Cuts Jobs in Europe
- Intel (NASDAQ:INTC) Names New AI Chip Line “Jaguar Shores”
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
